China Touts First COVID Antibody Approval But Border Opening Eludes
Brii Gains First Product Nod
Executive Summary
The first antibody approval for COVID-19 in China comes amid variant threats and a continued strict Zero COVID policy.
You may also be interested in...
Brii’s Cocktail Active Against Coronavirus Subvariants, But Will It Succeed On The Market?
The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.
Brii Launches COVID Antibody As Shanghai Tightens Restrictions
Six months after Brii obtained Chinese approval for its antibody combo for COVID-19, the Beijing joint venture finally launches the drug in China.
China's 'Two Sessions': Vaccines, Drugs Seen Key To Easing Restrictions Amid New Spike
The latest policies from Beijing show that the Chinese government is readying its own new vaccines and drugs for COVID-19 in a bid to gradually ease some of the strictest pandemic restrictions globally, but progress is mixed and domestic reported infections are surging to their highest level since March 2020.